Literatura académica sobre el tema "Usher syndrome type 1J"
Crea una cita precisa en los estilos APA, MLA, Chicago, Harvard y otros
Consulte las listas temáticas de artículos, libros, tesis, actas de conferencias y otras fuentes académicas sobre el tema "Usher syndrome type 1J".
Junto a cada fuente en la lista de referencias hay un botón "Agregar a la bibliografía". Pulsa este botón, y generaremos automáticamente la referencia bibliográfica para la obra elegida en el estilo de cita que necesites: APA, MLA, Harvard, Vancouver, Chicago, etc.
También puede descargar el texto completo de la publicación académica en formato pdf y leer en línea su resumen siempre que esté disponible en los metadatos.
Artículos de revistas sobre el tema "Usher syndrome type 1J"
Riazuddin, Saima, Inna A. Belyantseva, Arnaud P. J. Giese, Kwanghyuk Lee, Artur A. Indzhykulian, Sri Pratima Nandamuri, Rizwan Yousaf et al. "Alterations of the CIB2 calcium- and integrin-binding protein cause Usher syndrome type 1J and nonsyndromic deafness DFNB48". Nature Genetics 44, n.º 11 (30 de septiembre de 2012): 1265–71. http://dx.doi.org/10.1038/ng.2426.
Texto completoJan, A. "Mutations in CIB2 calcium and integrin-binding protein disrupt auditory hair cell calcium homeostasis in Usher syndrome type 1J and non-syndromic deafnessDFNB48". Clinical Genetics 83, n.º 4 (abril de 2013): 317–18. http://dx.doi.org/10.1111/cge.12100.
Texto completoCastiglione, Alessandro y Claes Möller. "Usher Syndrome". Audiology Research 12, n.º 1 (11 de enero de 2022): 42–65. http://dx.doi.org/10.3390/audiolres12010005.
Texto completoPennings, Ronald J. E., August F. Deutman, Randall R. Fields, William J. Kimberling, Patrick L. M. Huygen y W. R. J. Cremers. "Usher Syndrome Type III Can Mimic other Types of Usher Syndrome". Annals of Otology, Rhinology & Laryngology 112, n.º 6 (junio de 2003): 525–30. http://dx.doi.org/10.1177/000348940311200608.
Texto completoReisser, Christoph F. V., William J. Kimberling y Christian R. Otterstedde. "Hearing Loss in Usher Syndrome Type II is Nonprogressive". Annals of Otology, Rhinology & Laryngology 111, n.º 12 (diciembre de 2002): 1108–11. http://dx.doi.org/10.1177/000348940211101208.
Texto completoKeats, Bronya J. B., Alexander A. Todorov, Larry D. Atwood, Mary Z. Pelias, J. Fielding Hejtmancik, William J. Kimberling, Mark Leppert, Richard A. Lewis y Richard J. H. Smith. "Linkage studies of usher syndrome type 1: Exclusion results from the usher syndrome consortium". Genomics 14, n.º 3 (noviembre de 1992): 707–14. http://dx.doi.org/10.1016/s0888-7543(05)80172-7.
Texto completoOuyang, Xiao Mei, Denise Yan, Li Lin Du, J. Fielding Hejtmancik, Samuel G. Jacobson, Walter E. Nance, An Ren Li et al. "Characterization of Usher syndrome type I gene mutations in an Usher syndrome patient population". Human Genetics 116, n.º 4 (20 de enero de 2005): 292–99. http://dx.doi.org/10.1007/s00439-004-1227-2.
Texto completoAarem, Annelies Van, Mariette Wagenaar, Alfred J. L. G. Pinckers, Patrick L. M. Huygen, Elisabeth M. Bleeker-wagemakers, Bill J. Kimberling y W. R. J. Cremers. "Ophthalmologic findings in Usher syndrome type 2A". Ophthalmic Genetics 16, n.º 4 (enero de 1995): 151–58. http://dx.doi.org/10.3109/13816819509057856.
Texto completoOuyang, XM, D. Yam, JF Hejtmancik, SG Jacobson, AR Li, LL Du, S. Angeli, M. Kaiser, T. Balkany y XZ Liu. "Mutational spectrum in Usher syndrome type II". Clinical Genetics 65, n.º 4 (16 de febrero de 2004): 288–93. http://dx.doi.org/10.1046/j.1399-0004.2004.00216.x.
Texto completoPieke Dahl, S., W. J. Kimberling, M. B. Gorin, M. D. Weston, J. M. Furman, A. Pikus y C. Moller. "Genetic heterogeneity of Usher syndrome type II." Journal of Medical Genetics 30, n.º 10 (1 de octubre de 1993): 843–48. http://dx.doi.org/10.1136/jmg.30.10.843.
Texto completoTesis sobre el tema "Usher syndrome type 1J"
Blaydon, Diana Claire. "Molecular genetics of Usher syndrome type 1C". Thesis, University College London (University of London), 2004. http://discovery.ucl.ac.uk/1446499/.
Texto completoJoensuu, Tarja. "Positional cloning of the usher syndrome type 3 gene (USH3)". Helsinki : University of Helsinki, 2002. http://ethesis.helsinki.fi/julkaisut/laa/kliin/vk/joensuu/.
Texto completoHenricson, Cecilia. "Cognitive capacities and composite cognitive skills in individuals with Usher syndrome type 1 and 2". Doctoral thesis, Linköpings universitet, Institutionen för beteendevetenskap och lärande, 2015. http://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-120114.
Texto completoFöreliggande avhandling tillhör ämnet handikappvetenskap och beskriver specifika kognitiva förmågor hos personer med Ushers syndrom typ 1 och 2. Avhandlingens ämne har undersökts utifrån ett tvärvetenskapligt perspektiv, även om de teorier som tillämpas och beskrivs huvudsakligen härrör inom området kognitiv psykologi. Ushers syndrom är en ovanlig genetisk åkomma som leder till kombinationen av syn- och hörselnedsättning: dövblindhet. Individer med typ 1 av syndromet har medfödd dövhet medan individer med typ 2 har en medfödd måttlig till grav hörselnedsättning. Någon gång i åldrarna 6-10 år börjar de första symptomen, till exempel nedsatt mörkerseende, på den genetiskt betingade progressiva synnedsättningen Retinitis Pigmentosa att framträda. Syndromet är väl beskrivet i forskningen med avseende på genetiska och medicinska aspekter, men det finns extremt lite tidigare forskning med kognitivt perspektiv om populationen. Studierna 1 och 2 i föreliggande avhandling fokuserade på barn med Ushers syndrom typ 1 och cochleaimplantat. Dessa studier undersökte fonologisk förmåga, lexikal access, arbetsminne och läsning i gruppen. Studie 3 undersökte samma kognitiva förmågor hos vuxna med typ 2 av syndromet. I studie 4 undersöktes även den sammansatta förmågan Theory of Mind hos de vuxna med typ 2 och deras prestation jämfördes både mot en kontroll grupp med normal hörsel och syn och en kontrollgrupp med annan typ av dövblindhet; Alström syndrom. Resultaten visade att både barnen och de vuxna med Ushers syndrom hade signifikant sämre fonologisk förmåga än kontrollgruppen med normal hörsel. Nivån på prestation varierade stort inom grupperna, särskilt mellan barnen med typ 1, och flera av individerna (barn och vuxna) presterade trots hörselnedsättningen på samma nivå som de normalhörande. Läsfärdigheten befanns vara i nivå med kontrollgrupperna. I den vuxna gruppen var det stor variation i prestation även på Theory of Mind, men de flesta av individerna presterade liknande som kontrollgruppen med normal hörsel och syn. Föreliggande projekt har resulterat i lite mer kunskap om kognitiva färdigheter hos individer med Ushers syndrom typ 1 och 2. De resultat som individerna med Ushers syndrome presterade kan till stor del förstås och tolkas genom tillämpning av teorier och modeller utvecklade för att den inverkan på kognitiva förmågor det har att ha nedsatt hörsel och höra med hjälp av hörselapparat eller cochleaimplantat. Dock tyder fynden i detta projekt även på att individer med Ushers syndrom på grund av den allvarliga synnedsättningen har ytterligare svårigheter att få tillgodogöra sig information, men i vilken utsträckning och på vilket sätt är ännu inte beskrivet. Utifrån fynden i föreliggande studie blev rekommendation att interventioner och stöd till personer med Ushers syndrom utformas specifikt till varje individ, med hänsyn taget både till hens grad av synnedsättning och hörselnedsättning.
Lahlou, Ghizlène. "Thérapie génique translationnelle des surdités et troubles vestibulaires d'origine génétique". Electronic Thesis or Diss., Sorbonne université, 2020. https://accesdistant.sorbonne-universite.fr/login?url=https://theses-intra.sorbonne-universite.fr/2020SORUS090.pdf.
Texto completoDeafness and vestibular disorders are frequent pathologies, and sources of disability and impaired quality of life. Deafness is the most common sensory disorder in humans, and 1 child is born deaf for every 700 births. Currently, there is no cure for these disorders. A promising therapeutic alternative is gene therapy using rAAV, and numerous preclinical studies have provided proof of its efficacy in the treatment of deafness and vestibular disorders of genetic origin. However, many challenges remain to be overcome before considering application in humans. In this work, we sought to identify the key steps to be taken for a clinical application of gene therapy for 2 human genetic causes of deafness, USH1G syndrome and DFNB9 deafness. We used the corresponding mouse models for this, as well as studies in non-human primates and an in vitro human vestibular organ explant model. We were able to show that the therapeutic window was a major factor to take into account in a translational objective. The stage of maturation of the inner ear greatly influences the effectiveness of therapy, especially when the pathology involves developmental abnormalities such as in USH1 syndrome. However, we were able to provide evidence of an extension of the therapeutic window in Ush1g-/- mice, and to show that viral gene therapy performed at a mature stage allowed vestibular function to be restored to a level close to normal, and to a lesser extent a restauration of hearing function. In DFNB9 deafness for which there is no developmental abnormality, we were able to show that gene therapy allowed a complete restoration of hearing, and laid the foundations for a future therapy in humans
Labbe, Ménélik. "Caractérisation fonctionnelle du complexe de transduction mécano-électrique des cellules ciliées du système auditif". Thesis, Paris 6, 2016. http://www.theses.fr/2016PA066543/document.
Texto completoUsher syndrome (USH) is characterised by a sensorineural congenital deafness and a progressive loss of vision by retinitis pigmentosa. During my PhD, my main focus of study was a gene responsible for Usher syndrome type 2, USH2A. This gene codes for usherin, a protein associated with the fibrous links located at the base of the hair bundle of cochlear, and vestibular hair cells. In mice, these transitory links start to disappear as of postnatal day 9 (P9), and the molecular complex with which they are associated is composed of usherin, adgrv1 (an adhesion G protein coupled receptor), whirlin, and pdzd7 (two submembranous PDZ domain-containing scaffold proteins). Previous work has shown that the interaction in between these 4 proteins is essential for the development of the hair bundle, the structure responsible for the initiation of the mechano-electrical transduction (MET) process in the hair cells. During my thesis, I studied the short term and long term effects of the absence of the longest of the 2 usherin isoforms, the transmembrane b-isoform, in mice carrying a mutation in the Ush2a gene (Ush2aΔTM/ΔTM). In these mice, I measured mechano-electrical currents, auditory brainstem responses, undertook auditory masking tests, and analysed scanning electron micrographs of cochlear hair bundles. Through this work, I showed that basal lateral links similar to ankle links could be observed on P4, and that MET currents were normal on P7. The absence of the long b-isoform of usherin actually has very little effect on the morphology or the function of the cochlear hair bundle in mice, until 3 or 4 months of age. As of 4 months old however, Ush2aΔTM/ΔTM mice suffer from a progressive hearing loss, and frequency selectivity defects, mainly cause by a dysfunction of outer hair cells. These results will further add to the debate on whether the hearing loss in Usher syndrome type 2A is progressive or not. Hearing loss in USH2A patients is generally considered non progressive, but several studies have given indication to the contrary. My work has shown that in mice, deafness caused by mutations to the Ush2a gene can also follow a progressive pattern. The potential existence of this temporal window in USH2A patients whose hearing impairment is less severe at birth, but gets worse over time, could allow clinicians to use gene therapy as curative treatment for patients who fall into this category
DELL'AQUILA, FABIO. "GENE THERAPY FOR GYRATE ATROPHY OF CHOROID AND RETINA AND FOR USH1B RETINITIS PIGMENTOSA". Doctoral thesis, Università degli Studi di Milano, 2021. http://hdl.handle.net/2434/884458.
Texto completoLin, Mei-Chu y 林美珠. "The Genetic Characteristics of an Usher Syndrome Type II Family". Thesis, 2010. http://ndltd.ncl.edu.tw/handle/42575941844580818735.
Texto completo國立台北護理學院
聽語障礙科學研究所
98
Usher syndrome type II (USH2), an autosomal recessive disorder, is the most common type of User syndrome and characterized by congenital moderate to severe sensorineural hearing loss and progressive retinitis pigmentosa. Up to date, there are 4 loci associated with USH2. Defects in the USH2A gene have been responsible for most cases of USH2, but the locations and frequency of mutation sites are different between ethnicities. In this report, we screened the entire coding region of USH2A isoform B for a Taiwan family with 2 USH2 patients and 9 relatives by direct sequencing, and uncovered 17 different sequence variations, including 15 polymorphism sites and 2 novel mutations. Thirteen of 15 polymorphism sites have been reported in previous publications related to Eastern Asian populations and 2, c.997T>C and c.7448T>G, are novel. The 2 novel mutations, c.2187C>A (p.C729X) and c.13852delG (p.A4618fs), are compound heterozygotes in this family. Our results indicate that the mutation spectrum of USH2A gene among Taiwan population may differ from non-Eastern Asian populations. The finding of the report provides information not only for clinical diagnoses and follow up patients of this family in the future but also for the development of novel clinical diagnoses tools and therapies.
Jorge, André Filipe Santos. "Molecular studies of a novel mutation in MYO7A gene in Usher Syndrome type I". Master's thesis, 2016. http://hdl.handle.net/10316/33413.
Texto completoIntrodução: O Síndrome de Usher (USH) é uma doença autossómica recessiva caracterizada por um quadro de défice auditivo neurosensorial e retinite pigmentar, associado ou não a disfunção vestibular. USH é dividido em três tipos, sendo o USH tipo I o mais grave, caraterizado por surdez grave a profunda bilateral congénita, disfunção vestibular e retinite pigmentar diagnosticada durante a infância. Nas famílias com USH tipo I, MYO7A é o gene mais frequentemente mutado (50%). Este gene codifica para a proteína Miosina VIIa, previamente descrita como uma proteína motor de transporte e participando na formação da adesão célula a célula. Num estudo anterior foi encontrada uma nova alteração (c.4489G>C) no gene MYO7A num doente português com USH tipo I. Este trabalho propôs-se a avaliar a possibilidade de esta alteração ser responsável pelo fenótipo. Métodos: Uma avaliação clínica completa foi feita de forma a confirmar o fenótipo do doente. As análises por Sequenciação do exão 34 do gene MYO7A da amostra do doente e por PCR-RFLP das amostras do doente e de 250 indivíduos normais sem USH foram efetuadas para avaliar a presença da alteração c.4489G>C. Adicionalmente, foram realizados estudos in silico, usando software disponíveis online e a conservação evolutiva num grupo de primatas e não primatas. Finalmente, para determinar a expressão da alteração c.4489G>C nos transcritos do gene MYO7A, foram estudadas amostras de epitélio nasal do doente e de dois indivíduos normais. Resultados/Discussão: Foi confirmada a presença da variante c.4489G>C no doente com USH do tipo I e a sua ausência em 250 indivíduos normais. Os softwares online usados demostraram que a variante era lesiva, provavelmente deletéria ou causadora da doença. O estudo da conservação evolutiva demonstrou uma região altamente conservada no genoma e na proteína, em todas as espécies estudadas. Foi ainda possível identificar a expressão da variante c.4489G>C nos transcritos da amostra do doente e a sua ausência nas amostras dos indivíduos normais. Conclusão: Assim, foi possível concluir que a nova alteração c.4489G>C do gene MYO7A é uma mutação missense homozigótica, provavelmente responsável pelo USH do tipo I no doente português e que a sua expressão foi encontrada nos transcritos do epitélio nasal do doente. Usher syndrome (USH) is an autosomal recessive disorder characterized by the association of a sensorineural hearing impairment and retinitis pigmentosa, with or without vestibular dysfunction. USH is divided in three types, being USH type I the most severe form, characterized by severe to profound congenital and bilateral sensorineural hearing loss, congenital vestibular dysfunction and retinitis pigmentosa diagnostic during childhood. In USH type I families, MYO7A is the most commonly mutated gene (50%). This gene codes for Myosin VIIa protein, previously described as a motor transport protein and participating in the establishment of cell-cell adhesions. In a previous study, it was found a novel homozygous variant (c.4489G>C) in MYO7A gene in an USH type I Portuguese patient. This work purposed to appraise the possibility of this variant be responsible for the phenotype. A complete evaluation was performed to ascertain the clinical phenotype of the patient. Patient’s sample Sequencing analysis of MYO7A gene exon 34 and PCR-RFLP analysis of patient and 250 DNA samples from normal individuals without USH was accomplished to assess the c.4489G>C variant presence. Additionally, in silico studies using available internet software and evolutionary conservation in a group of primates and non-primates was performed. Finally, in order to determine if the c.4489G>C variant allele was expressed in MYO7A gene transcripts, nasal epithelium samples from the patient and two normal individuals were studied. The presence of c.4489G>C variant in an USH type I patient and its absence in 250 normal individuals was confirmed. Internet software used determined that this variant was probably damaging, deleterious or disease causing. Evolutionary conservation study showed a highly conserved region both in nucleotide and amino acid sequences from Homo sapiens to Molecular studies of a novel mutation in MYO7A gene in Usher Syndrome type I 13 Caenorhabditis elegans. Expression of c.4489G>C variant in patient’s cDNA sample was identified as well as its absence in the two normal individuals cDNA samples. In conclusion, this study revealed that the novel c.4489G>C MYO7A gene variant is a homozygous missense mutation, probably responsible for USH type 1 in a Portuguese patient and its expression found in patient’s nasal epithelium transcripts.
Lin, Wen-Ying y 林雯英. "Identification & functional analysis of a novel mutant allele, MYO7A c.6335C>G(p.S2112*) of Usher syndrome type II". Thesis, 2019. http://ndltd.ncl.edu.tw/handle/8a754u.
Texto completoLibros sobre el tema "Usher syndrome type 1J"
The madness of Usher's: Coping with vision and hearing loss (Usher syndrome type II). Corpus Christi, Tex: Business of Living Publications, 1991.
Buscar texto completoCapítulos de libros sobre el tema "Usher syndrome type 1J"
Ayyagari, Radha, Anren Li, Ann Nestorowicz, Yan Li, Richard J. H. Smith, M. Alan Permutt y J. Fielding Hejtmancik. "Usher Syndrome Type 1C". En Degenerative Retinal Diseases, 303–12. Boston, MA: Springer US, 1997. http://dx.doi.org/10.1007/978-1-4615-5933-7_33.
Texto completoAyyagari, Radha, Richard J. H. Smith, Elizabeth C. Lee, William J. Kimberling, Marcelle Jay, Alan Bird y J. Fielding Hejtmancik. "Heterogeneity of Usher Syndrome Type I". En Retinal Degeneration, 127–33. Boston, MA: Springer US, 1993. http://dx.doi.org/10.1007/978-1-4615-2974-3_12.
Texto completoWilliams, David S. y Vanda S. Lopes. "Gene Therapy Strategies for Usher Syndrome Type 1B". En Retinal Degenerative Diseases, 235–42. Boston, MA: Springer US, 2011. http://dx.doi.org/10.1007/978-1-4614-0631-0_31.
Texto completoBork, J. M., R. J. Morell, S. Khan, S. Riazuddin, E. R. Wilcox, T. B. Friedman y A. J. Griffith. "Clinical Presentation of DFNB12 and Usher Syndrome Type 1D". En Advances in Oto-Rhino-Laryngology, 145–52. Basel: KARGER, 2002. http://dx.doi.org/10.1159/000066829.
Texto completoNagel-Wolfrum, Kerstin, Timor Baasov y Uwe Wolfrum. "Therapy Strategies for Usher Syndrome Type 1C in the Retina". En Retinal Degenerative Diseases, 741–47. New York, NY: Springer New York, 2014. http://dx.doi.org/10.1007/978-1-4614-3209-8_93.
Texto completo